Recipient versus location
A parcel is delivered to an address. A medication is delivered to a person, or to someone authorised to accept for them. “Left at door” is a successful parcel outcome and an unanswered question in pharmacy.
Apex topic
Pharmaceutical logistics
Moving medication is not a hard transport problem. It is a hard evidence problem wearing a transport problem’s clothes. This page explains what pharmaceutical logistics is, why parcel networks are structurally the wrong shape for it, which parts of the chain NoazRX operates and which it does not, and how to evaluate anyone who says they can do it.
What is pharmaceutical logistics?
Pharmaceutical logistics is the movement, handling and documentation of medication across the licensed parties that hold it: manufacturers, wholesalers and distributors, central-fill operations, pharmacies, hospitals and care facilities, and ultimately patients. It covers the transport itself, the conditions the product is kept in while it moves, the record of who held it at each point, and the evidence that it reached the person or site it was meant to reach.
The word covers a chain much longer than any one company operates. Manufacturing, primary distribution, licensed storage and dispensing are each their own regulated activity. NoazRX operates two transport stages inside that chain — the regional movement between licensed sites, and the final mile out to patients and care settings — and produces the record for both.
The core difference
How it differs from ordinary parcel delivery
Not speed, and not fragility. Parcel networks move urgent and fragile things well. The difference is what each system is optimised to produce.
A parcel network is optimised for throughput: the largest number of items arriving somewhere plausible at the lowest cost per item. Everything that makes it efficient — consolidation, automated sortation, interchangeable handlers, delivery to a location rather than a person — is in direct tension with what pharmaceutical transport has to be able to prove afterwards.
Custody versus tracking
Tracking tells you where an item was scanned. Custody tells you who was accountable for it between scans, and is only meaningful if the handlers are identifiable. A network built on interchangeable handling cannot produce it retrospectively.
Condition as a property of the lane
A parcel network moves everything through the same sortation and dwell. A pharmaceutical lane has to know what its own dwell does to the product — which is a question about that lane, in that season, not about the carrier in general.
Failure as an outcome, not an exception
A parcel that cannot be delivered is a cost. A medication that cannot be delivered is a clinical event with a return leg, a documentation requirement and someone who needs to be told. It has to be designed for, not handled.
The record has to outlive the delivery
Parcel tracking data has a short useful life. A pharmacy may be asked about a delivery months later by a manager, a payer or a regulator, and needs a record built to be read then rather than a status that has since been archived.
Privacy is a design constraint
A manifest, a notification and a delivery photo can each disclose something about a person’s health. What appears on them is a decision, made once, in the system — not left to whoever prints the label.
None of this makes parcel carriers bad at their job. It makes them the wrong shape for this one. That comparison is drawn out further in healthcare delivery versus parcel shipping and healthcare logistics versus general couriers.
Scope
The part of the supply chain NoazRX addresses
Being specific about this matters more than it looks, because the honest answer excludes a great deal of what “pharmaceutical logistics” can mean.
What NoazRX does
- Regional and middle-mile transport between licensed sites
- Final-mile delivery to patients, LTC, hospitals and clinics
- Custody, temperature, proof-of-delivery and exception records produced as the work happens
- Returns and the reverse leg
- The dispatch, driver and recipient-communication software behind all of it
- Integration so those records land in the systems you already run
What NoazRX does not do
- Warehousing, storage or licensed holding of stock
- Picking, packing, labelling or fulfillment operations
- Dispensing, or any pharmacy practice activity
- Wholesale distribution
- Clinical-trial or investigational-product logistics
- Cross-border transport of medication, in either direction
Some of those exclusions used to be claims on this site. Pages describing fulfillment hubs and clinical-trial supply were retired in favour of saying plainly what the company is: a transport and evidence layer between parties who each hold their own licences and obligations.
Stage one
Regional and middle-mile pharmaceutical transport
The stage where the recipient is a licensed site rather than a person: a pharmacy, a store in a chain, a facility with a receiving process and an inventory system. It is the least visible part of the chain and the part where a single failure has the widest downstream effect, because one missed replenishment is every patient that pharmacy serves for the rest of the day.
The movements it covers
- Central fill to pharmacy — filled prescriptions out to the store that will hand them over, against a cut-off the store’s opening depends on
- Distribution point to pharmacy — the direct-to-pharmacy leg, also called secondary distribution
- Pharmacy replenishment — including the unscheduled short-fill run that exists because a store is out today
- Inter-store and pharmacy-to-pharmacy transfers — both ends licensed, both ends needing the transfer to reconcile in their own records
- Regional and inter-city legs — where distance rather than density is the constraint
Consolidation points and cross-docking are legitimate patterns to design a regional programme around, and are described as patterns rather than as facilities: NoazRX operates no warehouse or cross-dock, and where a programme uses a consolidation site, that site belongs to one of the parties in the chain. The full treatment is on regional pharmaceutical distribution; the long point-to-point case is inter-city medical transport.
Stage two
Final-mile pharmaceutical delivery
The last leg, and the only one with a person at the end of it. Everything difficult about this stage follows from that single fact: who may accept, what proves that they did, and what happens when nobody can.
The handoffs it covers
- Pharmacy to patient — no receiving desk, no scheduled window, and a leave-or-do-not-leave rule that belongs to the pharmacy rather than the driver
- Specialty pharmacy to patient — higher value, often refrigerated, and a therapy the patient cannot simply re-order
- Pharmacy to long-term care — scheduled cycles into a facility with its own med-pass timing and count procedures
- Hospital and clinic — discharge medication, ward movement, and facility access rules agreed before the first run
The stage is covered in full on pharmaceutical final-mile delivery. Readers who want it from one audience’s point of view should start with pharmacy delivery, prescription delivery, LTC medication logistics or hospital and clinic courier. Specimen movement is a different cargo type with its own stability rules and lives at lab and specimen transport.
Across both stages
The controls that make it pharmaceutical logistics rather than driving
Chain of custody
Custody is the unbroken, attributable record of who held the medication and when: scan events at each transfer, timestamps, driver identity, container or tote references, and a note on anything that departed from plan. It is a sequence, which is what distinguishes it from a delivery status. A status tells you where something ended up; custody tells you what happened to it, which is the question asked when something has gone wrong. NoazRX documents custody and produces auditable records of it; it does not certify custody, and it does not assume a pharmacy’s own controlled-substance obligations. See pharmaceutical chain of custody.
Proof of delivery
Proof of delivery is one event inside custody: the moment of handoff, and what was recorded about it. Who accepted, their relationship to the patient, a signature or a photo where a signature is not appropriate, timestamp and location context, and the reconciliation against what left the pharmacy. The relationship field is the one most often missing and the one a dispute most often turns on. See proof of delivery.
Temperature visibility and cold-chain-capable workflows
Temperature is a property of the lane, not of the carrier. Refrigerated and temperature-aware workflows can be configured where a programme’s requirements support them, with readings tied to the movement rather than kept in a separate system, and what a specific lane can hold is answered when that lane is designed.
Ambient product is where the industry is least careful, so we measured it. A single-use logger left in a delivery vehicle cabin for 165 continuous days recorded a high of 50.6 °C and a low of −14.4 °C, with a mean kinetic temperature of 23.7 °C. That is one vehicle, one logger position and one region — an environment, not a fleet, and not a stability determination about any product. It is published in full, with its source export and its limitations, in the research, and the control it informs is cold chain and refrigerated transport.
Exceptions, failed delivery and the return flow
Every programme has deliveries that do not complete. The difference between programmes is whether the remainder is documented or merely retried. Nobody available, refused receipt, wrong address, no building access, a count that does not match — each recorded with its reason in the words given, its attempt history, who was contacted, and what happened to the medication afterwards. See delivery exception documentation, and returns and reverse logistics for the leg back into a licensed environment.
API, TMS and reporting
The reason the transport and the software are one system here is that evidence captured after the fact is weaker than evidence captured during it. Orders arrive through the API or the dispatch interface, status flows back, and the delivery record exports into the systems the pharmacy or health system already runs — because a record that lives only in a supplier’s portal is a record you do not have. See healthcare TMS and delivery API and pharmacy delivery software.
Privacy
What appears on a manifest, in a notification and in a delivery photo can each disclose something about a person’s health. Those are configuration decisions made once, in the system. NoazRX builds privacy controls designed to support healthcare delivery obligations under HIPAA and PHIPA; that is a description of controls, not a certification, and it does not replace a healthcare organisation’s own compliance programme.
Transport quality
The vocabulary a quality function will use
Buyers whose organisation has a quality function will not ask about any of the above in the words used on this page. They will ask about carrier qualification and carrier review, route and lane profiles, written transportation procedures, qualified shipping systems and containers, monitoring devices, deviations and temperature excursions, contingency planning, and the receiving evidence that closes the loop at the destination.
That vocabulary comes largely from guidance written for drug establishments — in Canada, Health Canada’s GUI-0069 on temperature control during storage and transportation is the reference point most often cited. It is a useful and legitimate frame for pharmaceutical transport quality. It is also written for a specific set of regulated parties, and it should not be represented as imposing an identical legal obligation on every individual retail prescription delivery, nor is NoazRX certified, licensed or approved under it — there is no such certification to hold.
A dedicated treatment of carrier qualification and lane profiles is planned rather than published. It is being written against the guidance section by section rather than from recollection, which is the only responsible way to write a page that a quality function will read as authoritative. Until it exists, this section is the honest version of it.
Procurement
How to evaluate a pharmaceutical transport provider
These questions are as uncomfortable for us as for anyone else, which is the point of publishing them.
About the evidence
- Show me one completed delivery record in full — not a dashboard, one record.
- Is the temperature reading attached to this delivery, or to a vehicle and a time range I have to correlate myself?
- Who accepted it, and what field records their relationship to the patient?
- If a delivery is disputed in eight weeks, what can you produce, and how long is it kept?
- Can I export all of it into my own systems?
About the failures
- What is your exception rate, by reason, on a programme like mine — and can you show it rather than describe it?
- What happens to the medication at 6pm when the last attempt failed?
- Who decides whether a delivery may be left, and where is that decision recorded?
About the claims
- Which of these are you doing today, for whom, and which would need to be configured?
- Where does that number come from, and can I see the measurement?
- Is that a certification you hold, or a description of how you built something?
- Is this lane running now, or is this a city on a map?
The last question is the one this industry answers worst, ours included until recently. A capability the software supports is not a lane running near you, and a page that blurs the two is a page that will be corrected in a procurement call.
Coverage
Coverage planning, without a map of cities
NoazRX supports configured programmes in Canada and the United States, domestically on both sides — medication does not cross the border in either direction. Whether a particular lane can be operated is not a property of a city. It is decided by the lane: origin and destination and what each of them is, volume and rhythm, pickup readiness and receiving windows, temperature and custody requirements, building access, and local driver coverage on the days and hours the lane needs.
That is why this page names no served cities. Bring the lane and you get an answer about that lane. See how North American coverage is planned, Canada and the United States.
Pharmaceutical logistics questions
What is the difference between pharmaceutical logistics and healthcare logistics?
They overlap heavily and buyers use them interchangeably. Pharmaceutical logistics centres on the medication supply chain specifically; healthcare logistics is the broader category that also takes in specimens, supplies and equipment. Different buyer populations reach for different terms, which is why both pages exist and neither redirects to the other.
Is NoazRX a wholesale distributor or a 3PL?
Neither. NoazRX does not hold, store or own stock and does not dispense. It moves what licensed sites release and records the movement, which is a transport and evidence role rather than a distribution or storage one.
Do you handle clinical trial or investigational product logistics?
No. That carries obligations NoazRX has not taken on, and a page on this site previously implied otherwise. It has been retired.
Can you move medication across the Canada–US border?
No. Transport is domestic on both sides: Canadian prescriptions move with Canadian transport and U.S. prescriptions with U.S. transport.
Are you GDP certified or GUI-0069 compliant?
No, and neither is a certification a transport provider can hold in the way the question implies. NoazRX uses that guidance as a vocabulary for transport quality and designs its records to support the obligations its customers carry. Anyone claiming certification under it is worth asking to produce it.
How fast can you deliver?
Service levels are designed around route requirements, so a duration published on a page would be a number about no particular route. What determines it is distance, pickup readiness, building access and whether the receiving site can accept out of cycle. See how service levels are designed and same-day and STAT delivery.
Bring us a lane and a failure case
Where medication starts, where it has to arrive, at what volume and rhythm, with what temperature and custody requirements — and what your programme does today when a delivery does not complete. That is enough for a straight answer about what we would run, what we would change, and what we would decline.